---
title: "Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284957798.md"
description: "Summit Therapeutics PLC (SMMT) has flagged a significant going-concern risk due to insufficient cash and short-term investments to fund operations for the next twelve months. The company's reliance on uncertain external financing may lead to operational cutbacks or cessation of activities if capital cannot be raised. Despite this, the average stock price target is $31.25, indicating a potential upside of 93.92%."
datetime: "2026-05-02T06:00:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284957798.md)
  - [en](https://longbridge.com/en/news/284957798.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284957798.md)
---

# Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing

Summit Therapeutics PLC (SMMT) has disclosed a new risk, in the Debt & Financing category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Summit Therapeutics PLC is exposed to material going-concern risk, as its existing cash, cash equivalents, and short-term investments are insufficient to fund planned operations for the twelve months following issuance of its March 31, 2026 unaudited financial statements. The company’s reliance on uncertain external financing heightens the prospect of operational cutbacks, program delays, or an eventual cessation of activities if capital cannot be raised on acceptable terms.

The average SMMT stock price target is $31.25, implying 93.92% upside potential.

To learn more about Summit Therapeutics PLC’s risk factors, click here.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22](https://longbridge.com/en/news/286816644.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)